Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Return on Sales (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Return on Sales for 16 consecutive years, with 0.05% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales rose 58.0% to 0.05% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.01%, a 36.0% increase, with the full-year FY2025 number at 0.01%, up 39.0% from a year prior.
  • Return on Sales was 0.05% for Q4 2025 at Anika Therapeutics, down from 0.03% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.17% in Q2 2021 to a low of 5.33% in Q4 2023.
  • A 5-year average of 0.48% and a median of 0.08% in 2022 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: plummeted -315bps in 2023, then soared 470bps in 2024.
  • Anika Therapeutics' Return on Sales stood at 0.16% in 2021, then plummeted by -1249bps to 2.18% in 2022, then tumbled by -144bps to 5.33% in 2023, then skyrocketed by 88bps to 0.63% in 2024, then soared by 92bps to 0.05% in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Return on Sales are 0.05% (Q4 2025), 0.03% (Q3 2025), and 0.02% (Q2 2025).